Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
Clinical trial NCT02254044 · TERMINATED
Trial details
- NCT number
- NCT02254044
- Sponsor
- Boehringer Ingelheim
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2003-10-01
- Primary completion
- 2004-11-01
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.